Status:

COMPLETED

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

Lead Sponsor:

Affective Neuroscience Laboratory

Collaborating Sponsors:

Massachusetts General Hospital

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

18-64 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.

Detailed Description

A cardinal feature of Major Depressive Disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. In order to understand reward processing in depressed individuals it is also...

Eligibility Criteria

Inclusion

  • Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse)
  • Non-Smoker
  • Right-handed (Chapman and Chapman 1987)
  • Ability to provide informed consent

Exclusion

  • Predisposition to seizure (e.g. family history of a seizure disorder, history of head trauma) or current use of medications that lower the seizure threshold
  • History or current diagnosis of anorexia or bulimia
  • Alcohol or substance abuse within the past year
  • Current usage of Wellbutrin or Zyban or other drugs that contain bupropion
  • Recent discontinuation of alcohol or sedatives (including benzodiazepines)
  • Use of (in the last 2 weeks) medications that may have antidepressant properties (ex. some herbal supplements)
  • Known allergies to bupropion
  • Currently lactating, pregnant or believe you are likely to be pregnant (enrolled subjects who are not using reliable contraception and have engaged in sexual intercourse since their last menstrual period will be given a self-administered pregnancy test.)
  • Left-handed/ambidextrous
  • Evidence of neurological illness
  • Serious suicide or homicide risk
  • Concomitant medications other than those listed in the exclusion criteria will be considered on an individual basis. Oral contraceptives will be allowed.

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2007

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00205946

Start Date

April 1 2005

End Date

July 1 2007

Last Update

December 6 2007

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

The Depression Clinical and Research Program, Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Affective Neuroscience Laboratory, Department of Psychology, Harvard University

Cambridge, Massachusetts, United States, 02138